PC
MACK

PointState Capital’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

PointState Capital’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-44,485
Closed -$2.93M – 146
2016
Q1 		$2.93M Buy
+44,485
New +$2.32M 0.08% 71

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

PointState Capital's MACK Position: Q2 2016 in Review

PointState Capital sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2016, closing a stake of 44,485 shares — an estimated $2.93M sold.

PointState Capital first reported a position in MACK in Q1 2016 and held it in 1 quarter. The position peaked at $2.93M in Q1 2016. 140 funds tracked by Wall St. Rank hold MACK as of Q2 2016.

  • PointState Capital reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • PointState Capital sold 44,485 Merrimack Pharmaceuticals, Inc. shares in Q2 2016, an estimated $2.93M.
  • PointState Capital first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2016 and held it in 1 quarter.
  • PointState Capital's Merrimack Pharmaceuticals, Inc. position peaked at $2.93M in Q1 2016.
  • 140 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2016.

Based on PointState Capital's 13F filing for Q2 2016, filed 15 Aug 2016.